Background: The TE-PROVE post-market registry is evaluating clinical outcomes for patients receiving the third-generation, paclitaxel-eluting, platinum chromium TAXUS ElementÔ stent (Boston Scientific, Natick, MA) over 5 years in a real-world setting. This is the first report of results from this large multicenter registry. Methods: This was a prospective, open-label, multicenter observational 'all-comers' study that included 1014 patients at 37 sites in Europe. Follow-up was at 30 days, 6 months, and 1 year, and will continue annually through 5 years. The primary endpoint was the overall and TAXUS Element stent-related target vessel failure rate (TVF, defined as cardiac death, and target vessel-related myocardial infarction [MI] and reintervention [TVR]) at 1 year post-implantation. Secondary endpoints included the components of TVF, all-cause mortality, and ARC definite/probable stent thrombosis. Results: Among 1014 enrolled patients, 1-year clinical follow-up or death occurred in 97.3% (987/1014) of patients. Patients were 75.0% male (760/1014), mean age was 65.1AE10.8 years, 25.5% had medically treated diabetes (259/1014), and 10.7% (109/ 1014) were treated for STEMI. At baseline, mean lesion length among 1299 treated lesions was 19.8AE12.0 mm and mean reference vessel diameter was 3.1AE0.5 mm.
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Safety and Efficacy of Everolimus-Eluting Stents Versus Zotarolimus-Eluting Stents for 3-year of Follow-Up in Real-World Practice Young Jin Youn 1 , Sung Gyun Ahn 1 , Ji Hyun Lee 1 , Jun-Won Lee 1 , Seung Hwan Lee 1 , Junghan Yoon 1 1 Yonsei University Wonju College of Medicine, Wonju, Korea, Republic of Background: There are limited data for comparing the safety and efficacy of everolimus-eluting stent (EES) versus zotarolimus-eluting stents (ZES-R) for long-term follow-up. This study evaluated the safety and efficacy of these two stents in realworld practice for 3-year of follow-up. Methods: 926 patients who treated with EES (Xience V, Abbott Vascular, USA; n ¼459) and ZES-R (Endeavor Resolute, Medtronic Cardiovascular, USA; n ¼ 467) were analyzed using single center registry from 2008 to 2010 after excluding the patients with cardiogenic shock at admission and the patients with in-hospital mortality for reducing the potential selection bias. Primary endpoint was a composite of any death, any myocardial infarction, and target vessel-revascularization at 3-year of follow-up. Results: ZES-R group was younger (64.5 AE 10.8 year vs. 66.0 AE 10.2 year, p ¼ 0.033) then EES group but other baseline characteristics and laboratory findings were similar between two groups. EES was more used for left main lesion (9.8% vs. 3.9%, p < 0.001) but ZES-R was more used for right coronary artery (30.3% vs. 41.3%, p < 0.001). Although implanted number of stent was not different between two groups, EES was larger in diameter (3.11 AE 0.42 mm vs. 3.06 AE 0.40 mm, p ¼ 0.026) and shorter in length (40.2 AE 24.7 mm vs. 45.3 AE 25.7 mm, p ¼ 0.002) compared with ZES-R. Discharge medication was not different between two groups. During 3-year of follow-up (920 AE 206 days in EES group vs. 900 AE 216 days in ZES-R group, p ¼ 0.152), primary endpoint was not different between two groups (14.4% in EES group vs. 16.3% in ZES-R group, p ¼ 0.466). Stent thrombosis was similar between two groups (0.9% vs. 1.3%, p ¼ 0.387). Conclusions: In this real-world registry with unrestricted use of EES and ZES-R, two new generation drug-eluting stent showed comparable safety and efficacy during longterm follow-up. Background: The ION Registry assessed clinical outcomes for the thin-strut, IONÔ (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Coronary Stent System (Boston Scientific, Natick, MA) in unselected patients. This is the first report of results from this large multicenter registry.
Methods:
This prospective, open-label registry enrolled the first 1120 consenting patients treated with the ION stent for any indication at 40 clinical sites in the United States. Follow-up was at discharge, 30 and 180 days, and annually to 5 years. The primary endpoint was the 1-year rate of cardiac death or MI in PERSEUS-like patients (JACC 2010; 56:264-71) . Per protocol, the primary endpoint result from the ION registry was also combined with the European post-approval registry (TE-PROVE), which enrolled 306 PERSEUS-like patients, and the PERSEUS WH/SV populations (N¼1166). Results: 1111 patients received a study stent, 316 were PERSEUS-like, and 1-year follow-up was 92.1% (1023/1111). Most patients were male (70.3%, 781/1111) with a mean age 64.1AE11.0 years. At 1 year, the primary endpoint of CD/MI occurred in 2.1% (6/292) of PERSEUS-like patients in ION and 2.3% (40/1729) patients in the combined analysis. The upper 1-sided 95% CI for the combined analysis was 2.9%, which was significantly less than the prespecified performance goal of 7.6% (P<0.001). Secondary endpoints and subsets are given in the Table. Conclusions: The 1-year results of the ION U.S. Post-Approval Study confirm the safety and effectiveness of the ION stent for the treatment of coronary artery disease in everyday clinical practice. 
